Leerink Partners Maintains Outperform on Regenxbio, Raises Price Target to $20

Benzinga · 1d ago
Leerink Partners analyst Mani Foroohar maintains Regenxbio (NASDAQ:RGNX) with a Outperform and raises the price target from $16 to $20.